The sanofi pasteur candidate dengue tetravalent vaccine (TV) is a recombinant live
attenuated vaccine. It is based on a backbone of yellow fever vaccine (YF 17D) replication …

Background. Because infection with any of the 4 Dengue virus serotypes may elicit both
protective neutralizing antibodies and nonneutralizing antibodies capable of enhancing …

Dengue vaccine development has reached a major milestone with the initiation, in 2010, of
the first phase III clinical trial to investigate the Sanofi Pasteur CYD tetravalent dengue …

Dengue is the most prevalent mosquito-borne viral disease worldwide. Yet, there are no
vaccines or specific antivirals available to prevent or treat the disease. Several dengue …

Dengue virus is the most widespread geographically of the arboviruses and a major public
health threat in the tropics and subtropics. Scientific advances in recent years have provided …

Dengue virus (DENV) is a mosquito-borne member of the Flavivirus genus and includes four
serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), each of which is capable of causing …

Dengue viruses (DENV) currently infect approximately 400 million people each year causing
millions to seek care and overwhelming the health care infrastructure in endemic areas …

Dengue is a significant threat to public health worldwide. Currently, there are no licensed
vaccines available for dengue. Takeda Vaccines Inc. is developing a live, attenuated …

Dengue is the most important arboviral disease world-wide with an estimated 400 million
annual infections. Dengvaxia™ is a live attenuated tetravalent vaccine recently licensed for …

Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine
(CYD-TDV) that is in late-stage development. The present review summarizes the different …